ArticleJournal of thoracic disease2018
High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma.
Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Identifying Chemokine System-Related Phenotype to Predict Immune Feature in Pan-Cancer and Prognostic Signature for Lung Adenocarcinoma.Journal of inflammation research · 2025Article
- Transcriptional Inflammatory Signature in Healthy Donors and Different Radiotherapy Cancer Patients.International journal of molecular sciences · 2024Article
- Review
- CCL17 and CCL22 chemokines are upregulated in human obesity and play a role in vascular dysfunction.Frontiers in endocrinology · 2023Article
- Dishevelled Segment Polarity Protein 3: A Novel Prognosis-related Marker in Pan-driver-gene-negative Lung Adenocarcinoma.Journal of Cancer · 2023Article
- CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy.International journal of molecular sciences · 2022Review
- Regulation of Tumor and Metastasis Initiation by Chemokine Receptors.Journal of Cancer · 2022Review
- A prediction model integrated genomic alterations and immune signatures of tumor immune microenvironment for early recurrence of stage I NSCLC after curative resection.Translational lung cancer research · 2022Article
- Chemokine Receptor Antagonists: Role in Oncology.Current oncology reports · 2021Review
- Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Gene Expression Profiling of B Cell Lymphoma in Dogs Reveals Dichotomous Metabolic Signatures Distinguished by Oxidative Phosphorylation.Frontiers in oncology · 2020Article
- Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.Immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical trials of anti-CCR4 antibody for solid cancers with or without other immune-modulating agents including immune checkpoint blockade therapy are currently underway. However, little is known about the roles of CCR4
methodsFirst, the prognostic impact of
resultsHigher than median expression of the
conclusionsHigh CCR4 expression in the tumor microenvironment may be a poor prognostic factor in lung adenocarcinoma. Patients with high CCR4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.